Valuation: Medtide Inc.

Market Cap 2.89B 3.33B 425M 372M 343M 320M 603M 40.14B 617M 4.13B 1.59B 19.8B 1.59B 1.56B 68.74B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.99B 2.29B 292M 256M 236M 221M 415M 27.64B 425M 2.84B 1.1B 13.64B 1.1B 1.07B 47.35B EV / Sales 2026 *
2.91x
EV / Sales 2027 * 2.06x
Free-Float
23.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.62%
1 week-1.87%
Current month+6.26%
1 month+11.27%
3 months+7.44%
6 months-23.31%
Current year-24.21%
1 week 22
Extreme 22
24.2
1 month 19
Extreme 19
24.5
Current year 19
Extreme 19
30.46
1 year 19
Extreme 19
41.72
3 years 19
Extreme 19
41.72
5 years 19
Extreme 19
41.72
10 years 19
Extreme 19
41.72
Manager TitleAgeSince
Chief Executive Officer 58 11/06/2020
Director of Finance/CFO 53 01/10/2020
Investor Relations Contact 50 01/09/2023
Director TitleAgeSince
Chairman 58 11/06/2020
Director/Board Member 51 27/01/2022
Director/Board Member 63 27/01/2022
Date Insider Type Main position Quantity % Market Cap.
09/03Other

Chief Executive Officer

68,201,112 48.0967%
09/03Other

Director

68,201,112 48.0967%
09/03Other

Director

68,201,112 48.0967%
Change 5-day change 1-year change 3-year change Capi.($)
-1.62%-1.87% - - 400M
+0.94%+7.83%-4.77%+3.17% 46.2B
+5.79%+16.17%+421.86%+634.63% 38.71B
+1.12%+15.18%+22.74%-12.71% 31.9B
+3.61%+6.69%+20.23%+62.38% 31.12B
+8.02%+6.35%+17.67%+34.73% 23.77B
+1.13%+15.66% - - 16.2B
+1.45%+17.35%+72.11%+127.60% 15.05B
-1.13%+7.40%+12.03%+20.67% 13.74B
-0.60%+6.32%+102.74%+96.28% 13.42B
Average +1.87%+10.19%+83.08%+120.84% 23.05B
Weighted average by Cap. +2.70%+11.40%+95.90%+142.91%

Financials

2026 *2027 *
Net sales 684M 789M 101M 88.11M 81.34M 75.96M 143M 9.51B 146M 979M 378M 4.69B 378M 370M 16.3B 876M 1.01B 129M 113M 104M 97.23M 183M 12.18B 187M 1.25B 484M 6.01B 484M 473M 20.86B
Net income - -
Net Debt -898M -1.04B -132M -116M -107M -99.72M -188M -12.49B -192M -1.29B -496M -6.16B -496M -485M -21.39B -1.08B -1.25B -159M -139M -129M -120M -226M -15.03B -231M -1.55B -597M -7.42B -597M -584M -25.75B
Logo Medtide Inc.
Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.
Employees
566
Date Price Change Volume
30/06/26 HKD 23.10 -1.62% 11,400
29/06/26 HKD 23.48 +6.05% 85,200
26/06/26 HKD 22.14 -3.66% 85,500
25/06/26 HKD 22.98 -2.96% 101,600
24/06/26 HKD 23.68 +0.59% 120,800
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
20.35CNY
Average target price
25.19CNY
Spread / Average Target
+23.78%

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 3880 Stock